Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Primary Target | Pathway | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|---|---|
| BT-20 | Ceritinib | 10.0 | ALK | RTK | -0.7365 | 0.84133 |
| Hs 578T | Abemaciclib | 10.0 | CDK4/6 | Cell cycle | -0.5825 | 0.84364 |
| MDA-MB-361 | Buparlisib | 10.0 | pan PI3K | PI3K/mTOR | -0.9584 | 0.84606 |
| MDA-MB-361 | Torin2 | 1.0 | mTOR/ATM/ATR | PI3K/mTOR | -0.9642 | 0.85473 |
| Hs 578T | AZD7762 | 10.0 | CHK1/2 | Cell cycle | -0.5983 | 0.86377 |
| MDA-MB-361 | Cediranib | 10.0 | VEGFR/cKIT | RTK | -0.9803 | 0.88037 |
| SUM159PT | Abemaciclib | 10.0 | CDK4/6 | Cell cycle | -0.4677 | 0.88367 |
| T47D | Ceritinib | 10.0 | ALK | RTK | -0.8550 | 0.88984 |
| MDA-MB-361 | Ceritinib | 10.0 | ALK | RTK | -0.9910 | 0.89628 |
| MDA-MB-361 | Taselisib | 10.0 | PI3Ka, g, d | PI3K/mTOR | -0.9902 | 0.90326 |